Acquired resistance to gefitinib: The contribution of mechanisms other than the T790M, MET, and HGF status

Lung Cancer

Volumn 68, Issue 2, 2010, Pages 198-203

  Onitsuka, Takamitsu ^a   Uramoto, Hidetaka ^a   Nose, Naohiro ^a   Takenoyama, Mitsuhiro ^a   Hanagiri, Takeshi ^a   Sugio, Kenji ^a   Yasumoto, Kosei ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Adenocarcinoma; EGFR TKI; Gefitinib; Lung cancer; Resistance

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; K RAS PROTEIN; SCATTER FACTOR; SCATTER FACTOR RECEPTOR;

ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; CANCER INVASION; CANCER RECURRENCE; CANCER RESISTANCE; CLINICAL ARTICLE; FEMALE; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LYMPH NODE METASTASIS; MALE; MISSENSE MUTATION; MUTATIONAL ANALYSIS; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, NEOPLASM; EXONS; FEMALE; GENETIC ASSOCIATION STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MET; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 77950460014     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2009.05.022     Document Type: Article

References (41)

1. Fukuoka M., Yano S., Giaccone G., Tamura T., Nakagawa K., Douillard J.Y., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003, 21:2237-2246.
2. Kris M.G., Natale R.B., Herbst R.S., Lynch T.J., Prager D., Belani C.P., et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003, 290:2149-2158.
3. Perez-Soler R., Chachoua A., Hammond L.A., Rowinsky E.K., Huberman M., Karp D., et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004, 22:3238-3247.
4. Kosaka T., Yatabe Y., Endoh H., Kuwano H., Takahashi T., Mitsudomi T. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 2004, 64:8919-8923.
5. Sugio K., Uramoto H., Ono K., Oyama T., Hanagiri T., Sugaya M., et al. Mutations within the tyrosine kinase domain of EGFR gene specifically occur in lung adenocarcinoma patients with a low exposure of tobacco smoking. Br J Cancer 2006, 94:896-903.
6. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139.
7. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
8. Pao W., Miller V., Zakowski M., Doherty J., Politi K., Sarkaria I., et al. EGF receptor gene mutations are common in lung cancers from " never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004, 101:13306-13311.
9. Sordella R., Bell D.W., Haber D.A., Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004, 305:1163-1167.
10. Huang S.F., Liu H.P., Li L.H., Ku Y.C., Fu Y.N., Tsai H.Y., et al. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res 2004, 10:8195-8203.
11. Han S.W., Kim T.Y., Hwang P.G., Jeong S., Kim J., Choi I.S., et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 2005, 23:2493-2501.
12. Tokumo M., Toyooka S., Kiura K., Shigematsu H., Tomii K., Aoe M., et al. The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clin Cancer Res 2005, 11:1167-1173.
13. Mitsudomi T., Kosaka T., Endoh H., Horio Y., Hida T., Mori S., et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 2005, 23:2513-2520.
14. Shigematsu H., Lin L., Takahashi T., Nomura M., Suzuki M., Wistuba I.I., et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005, 97:339-346.
15. Uramoto H., Sugio K., Oyama T., Ono K., Sugaya M., Yoshimatsu T., et al. Epidermal growth factor receptor mutations are associated with gefitinib sensitivity in non-small cell lung cancer in Japanese. Lung Cancer 2006, 51:71-77.
16. Kobayashi S., Boggon T.J., Dayaram T., Jänne P.A., Kocher O., Meyerson M., et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005, 352:786-792.
17. Pao W., Miller V.A., Politi K.A., Riely G.J., Somwar R., Zakowski M.F., et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005, 2:1-11.
18. Kosaka T., Yatabe Y., Endoh H., Yoshida K., Hida T., Tsuboi M.T., et al. Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res 2006, 12:5764-5769.
19. Uramoto H., Sugio K., Oyama T., Sugaya M., Hanagiri T., Yasumoto K. A resistance to gefitinib. Int J Clin Oncol 2006, 11:487-491.
20. Yano S., Nakataki E., Ohtsuka S., Inayama M., Tomimoto H., Edakuni N., et al. Retreatment of lung adenocarcinoma patients with gefitinib who had experienced favorable results from their initial treatment with this selective epidermal growth factor receptor inhibitor: a report of three cases. Oncol Res 2005, 15:107-111.
21. Pao W., Wang T.Y., Riely G.J., Miller V.A., Pan Q., Ladanyi M., et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005, 2:e17.
22. Engelman J.A., Zejnullahu K., Mitsudomi T., Song Y., Hyland C., Park J.O., et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316:1039-1043.
23. Yano S., Wang W., Li Q., Matsumoto K., Sakurama H., Nakamura T., et al. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res 2008, 68:9479-9487.
24. Sobin L.H., Wittekind C. TNM classification of malignant tumors 2002, Wiley, New York. 6th ed.
25. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216.
26. Okuda K., Sasaki H., Yukiue H., Yano M., Fujii Y. Met gene copy number predicts the prognosis for completely resected non-small cell lung cancer. Cancer Sci 2008, 99:2280-2285.
27. Kato S., Funakoshi H., Nakamura T., Kato M., Nakano I., Hirano A., et al. Expression of hepatocyte growth factor and c-Met in the anterior horn cells of the spinal cord in the patients with amyotrophic lateral sclerosis (ALS). Acta Neuropathol 2003, 106:112-120.
28. Allred D.C., Harvey J.M., Berardo M., Clark G.M. Prognostic and predictive factors in breast canceer by immunohistochemical analysis. Mod Pathol 1998, 11:155-168.
29. Kohno K., Uchiumi T., Niina I., Wakasugi T., Igarashi T., Momii Y., et al. Transcription factors and drug resistance. Eur J Cancer 2005, 41:2577-2586.
30. Gow C.H., Shih J.Y., Chang Y.L., Yu C.J. Acquired gefitinib-resistant mutation of EGFR in a chemonaive lung adenocarcinoma harboring gefitinib-sensitive mutation L858R. PLoS Med 2005, 2:e269.
31. Kwak E.L., Sordella R., Bell D.W., Godin-Heymann N., Okimoto R.A., Brannigan B.W., et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci USA 2005, 102:7665-7670.
32. Choong N.W., Dietrich S., Seiwert T.Y., Tretiakova M.S., Nallasura V., Davies G.C., et al. Gefitinib response of erlotinib-refractory lung cancer involving meninges-role of EGFR mutation. Nat Clin Pract Oncol 2006, 3:50-57.
33. Uramoto H., Uchiumi T., Izumi H., Kohno K., Oyama T., Sugio K., et al. A new mechanism for primary resistance to gefitinib in lung adenocarcinoma: the role of a novel G796A mutation in exon 20 of EGFR. Anticancer Res 2007, 27:2297-2303.
34. Costa D.B., Halmos B., Kumar A., Schumer S.T., Huberman M.S., Boggon T.J., et al. BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. PLoS Med 2007, 4:1669-1679.
35. Balak M.N., Gong Y., Riely G.J., Somwar R., Li A.R., Zakowski M.F., et al. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res 2006, 12:6494-6501.
36. Inukai M., Toyooka S., Ito S., Asano H., Ichihara S., Soh J., et al. Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer. Cancer Res 2006, 66:7854-7858.
37. Engelman J.A., Mukohara T., Zejnullahu K., Lifshits E., Borrás A.M., Gale C.M., et al. Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. J Clin Invest 2006, 116:2695-2706.
38. Bean J., Brennan C., Shih J.Y., Riely G., Viale A., Wang L., et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A 2007, 104:20932-20937.
39. Kalikaki A., Koutsopoulos A., Trypaki M., Souglakos J., Stathopoulos E., Georgoulias V., et al. Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC. Br J Cancer 2008, 99:923-929.
40. Gow C.H., Chang Y.L., Hsu Y.C., Tsai M.F., Wu C.T., Yu C.J., et al. Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer. Ann Oncol 2009, 20:696-702.
41. Yoshimura N., Kudoh S., Kimura T., Mitsuoka S., Matsuura K., Hirata K., et al. EKB-569, a new irreversible epidermal growth factor receptor tyrosine kinase inhibitor, with clinical activity in patients with non-small cell lung cancer with acquired resistance to gefitinib. Lung Cancer 2006, 51:363-368.